News >

Expert Recaps Advances in AML

Caroline Seymour
Published: Wednesday, Sep 26, 2018

Dr. Rami S. Komrokji

Rami S. Komrokji, MD
Now that physicians have access to novel therapies for patients with acute myeloid leukemia (AML) following a 30-year gap in therapeutic development, physicians must now aim to understand their optimal placement in treatment, explained Rami S. Komrokji, MD.

State of the Science Summit™ on Hematologic Malignancies, Komrokji, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, reflected on the diverse AML treatment landscape and touched on the prognostic importance of biomarkers.

OncLive: How has the treatment landscape of AML changed in recent years?

Komrokji: It’s been an exciting time for researchers and patients. Now, we have more options that we can offer patients than we had in the past 30 years. In the last 2 years, we’ve witnessed the approval of several drugs in AML. I started the presentation by discussing the current risk stratification for AML, which is all based on cytogenetics and molecular data. I then went through all of the new drugs and where they are to be positioned in the management of patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication